HF 2564 allows pregnant minors in Iowa to legally consent to prenatal, intrapartum, and postnatal medical care from specific healthcare providers (including physicians, nurse practitioners, and emergency providers) if their parent, guardian, or legal custodian is not reasonably available. This directly affects pregnant minors who lack immediate adult support for their medical needs. The bill ensures minors can authorize care without parental involvement in these specific circumstances, while maintaining that healthcare providers must still obtain the minor’s informed consent. It does not change existing requirements for providers to secure consent directly from the minor patient.
This bill clarifies the authority of a health care decision-maker (attorney in fact) appointed under a durable power of attorney for health care in Iowa. It requires the decision-maker to follow the person's expressed wishes as written in the power of attorney, a separate life-sustaining procedures declaration, or communicated directly to them. The bill specifies that verbal requests to others or other documents cannot restrict the decision-maker's authority unless the power of attorney document explicitly states limitations. If the person's wishes are unknown, the decision-maker must act in their best interests based on medical condition and prognosis.
This bill requires Iowa public schools serving students in grades 7-12 to list the "Your Life Iowa" suicide prevention program's contact information (phone, text numbers, and website) as a resource on their school websites. It also mandates that schools issuing student ID cards to grades 7-12 must include this information on the cards, with schools serving grades 5-6 allowed to optionally include it. The law directly affects students in these grade levels by making suicide prevention resources more accessible through school-issued materials and online platforms. It does not change existing suicide prevention services but ensures schools proactively share this specific resource.
SF 319, titled "The Patient’s Right to Save Act," requires health care providers to disclose the discounted cash price for each specific service they accept as payment. Providers must share this price in advance, including any variations based on timing, location, or patient income, and inform patients that cash payments may not be cheaper than insurance-negotiated rates. The bill mandates annual reviews of these prices and requires clear communication about cash payment options to both insured and uninsured patients before services are provided. It directly affects health care providers who accept cash payments, aiming to increase price transparency for consumers.
SF 615 adds work requirements for participants in Iowa's health and wellness plan and Medicaid for employed people with disabilities, directly affecting eligible residents receiving these specific public assistance benefits. The bill requires individuals to meet certain work or training hours to maintain eligibility, alongside provisions for related funding mechanisms like the information technology fund and public assistance modernization fund. It became law after the Governor signed it on June 6, 2025, implementing these new eligibility conditions for the specified programs. The policy change modifies existing program rules without altering benefit amounts or creating new programs.
HF 1038 allocates funds from Iowa's opioid settlement to state agencies addressing the opioid crisis, directly affecting programs that provide treatment, prevention, and recovery services. The bill specifies how the money is distributed (disbursed) to eligible state entities and includes rules for when the funding takes effect, including retroactive application for prior periods. It does not change eligibility for the settlement funds but establishes the legal framework for their use. The bill passed unanimously and was signed into law by the Governor on June 6, 2025.
HF 383 would remove the pharmaceutical form of psilocybin (specifically crystalline polymorph COMP 360) from Iowa's Schedule I controlled substances list once the U.S. Food and Drug Administration (FDA) approves it and reschedules it under federal law. This would allow doctors to legally prescribe, distribute, and market COMP 360 for medical use, directly affecting healthcare providers and patients seeking this treatment. The bill automatically aligns Iowa law with federal FDA decisions on this specific pharmaceutical formulation. Note: The bill was vetoed by the governor on June 11, 2025, so it has not become law.
HF 330 requires health insurance plans to cover evidence-based treatment for autism spectrum disorder (ASD) for individuals diagnosed with ASD. It directly affects people with ASD who have health insurance, mandating that insurers provide this coverage without excessive cost-sharing. The bill establishes specific requirements for insurance companies to include ASD treatment services in their coverage, applying to most health insurance plans. This law, signed by the Governor on June 11, 2025, ensures that individuals with ASD can access necessary treatment through their insurance.
HF 516 creates priority access for residency and fellowship positions at the University of Iowa’s colleges of medicine and dentistry, directly affecting UI’s medical programs and their affiliated hospitals and clinics. The bill requires state-funded training programs to prioritize applicants from these UI institutions when filling medical residency and fellowship roles. Now law after Governor signed it on June 11, 2025, this policy change aims to strengthen UI’s medical education pipeline without altering broader admission standards for other institutions.
SF 383 requires pharmacy benefits managers (PBMs) to disclose drug pricing details and standardized fee structures to pharmacies and insurers. It limits certain PBM practices that affect prescription drug costs and establishes transparency rules for pharmacy services administrative organizations. The law directly affects PBMs, pharmacies, and insurance companies managing prescription drug benefits. Signed into law by the Governor on June 6, 2025, it aims to increase transparency in drug pricing and pharmacy billing.
